With more and more health-minded consumers turning to CBD products, producers are asking a crucial question: What do customers want?
SpectrumLeaf have spent a long time thinking about this and have arrived at a conclusion which defines their products: Accuracy, simplicity and discretion.
Their new Elevar Leafs product allows CBD users to take a highly accurate dose quickly and efficiently without any cumbersome packaging, any place, any time.
Their proprietary technology involves introducing specific and carefully measured quantities of water-soluble CBD to a piece of microfilm no larger than a postage stamp.
The consumer simply places the tab in their mouth and waits for it to dissolve, a quick and discreet way to take a 25mg dose of the compound.
CEO Felix Sundström – who is based in Stockholm, Sweden – told Cannabis Health why the customer’s perspective dominates how their new Elevar Leafs product works.
He said: “From a consumer point of view, we want to offer people a product that is accessible and simple.
“We try and avoid simply repeating what everybody else in the sector is doing and think of better ways of delivering CBD. We believe the functional aspect is very important and will only get more important going forward.”
Elevar Leafs come in three flavours – fresh mint, mint berry and lavender – and retails at less than £11 for five doses.
The discreet, carefully designed packaging could easily be mistaken for a business card, perfect for people who use CBD but don’t necessarily want to shout about it.
Based in Poland and with production in Las Vegas and California, SpectrumLeaf is already selling into 16 different European markets including the UK.
Launched two-and-a-half years ago and selling a range of products in 1,000 different outlets across the continent, the company is already making a splash in the UK market.
So why do people keep coming back for more?
Felix said: “With our product, the consumer knows exactly how much they’re taking every time they use it.
“We have three flavours and they all taste great – my favourite is the lavender – and they’re very discreet, they fit right into any pocket or bag and it’s easy to share with others too.
“There is a lack of CBD products out there which prioritise accuracy and discretion and we believe there’s a clear gap in the market for this.
“The packaging is very stylish too, it looks different and fresh.”
Making sure you are taking an accurate dose is a key concern for CBD customers looking to monitor the effects the product has on them.
Each 25 microgram dose is individually packaged in order to allow for a rigorous quality checking process that is carried out before products hit the shelves.
This delivery system also ensures users know exactly what they’re getting and are then able to alter the dose as needed.
The company recommends between 25 and 50mg per day but ultimately it is the customer who is in control.
Felix said: “Accuracy on dosing is very important because most people who use CBD are taking it for a specific purpose and want to be able to work out for themselves what is the right regular dose for them.
“When you look at other products like tinctures and oils, it is quite difficult to make sure you are taking the same amount every time and it’s easy to over or under dose.
“You can take more than one tab if necessary and I even know some people cut a tab in half if they want a smaller dose.
“This product gives you confidence you are taking the same amount of the product every time and you can easily take it with you if you need to travel or take your dose at an irregular time.
“That’s precisely why I use it myself – I think having that control over how much CBD you are consuming is essential to everyone.”
The company makes its extensive lab testing data available on its website to further ensure customer confidence in every product.
And unlike some CBD products, Elevar Leafs have a long shelf life too. You can keep them in a drawer for as long as a year and they will still be usable.
Products paid for securely over the company’s website can be shipped far and wide and usually arrive within one to four business days.
Repeat customers can sign up to a loyalty scheme and build up points in order to secure discounts.
As the CBD market expands, more and more consumers are coming round to the benefits of CBD.
Felix said: “Perceptions are definitely changing around CBD, awareness of the benefits to consumers and usage is going up day by day.”
For more visit www.elevarhemp.com
Combining CBD and CBG for the ultimate entourage effect
How much do you know about the 120 different cannabinoids in the cannabis plant? Browns CBD explains how CBD and CBG combine to offer different benefits
The plant actually produces over 120 cannabinoids with some being equally as impressive for certain issues. Browns CBD explains how CBG and CBD combine for the ultimate entourage effect.
By now you will have surely heard of CBD – the hemp-derived compound that has a plethora of health benefits and is incredibly safe to use.
Another important cannabinoid is CBG (Cannabigerol). This cannabinoid is commonly referred to as the ‘mother of all cannabinoids’ as it is the original molecule that most other cannabinoids are synthesized from.
In simple terms, hemp produces CBGa (the acidic form of CBG) in earlier stages of growth which is then converted within the plant into cannabinoids such as THCa, CBDa & CBCa. This can be seen in the diagram below.
CBG tends to be more expensive than CBD due to the fact that most varieties of hemp yield very low levels of CBG. And crops need to be harvested earlier to obtain significant levels of CBG for extraction. However, new CBG rich varieties of hemp are being developed to achieve greater yields.
CBD and CBG benefits
Studies on the benefits of CBG are fairly limited when compared to those of CBD, but there is some very promising preliminary evidence. Anecdotally, we have found customers to be very impressed with its calming effects on a range of issues.
CBG interacts with the endocannabinoid system differently from CBD. For those of you who don’t know, the endocannabinoid system is a significant bodily system made up of endocannabinoids, cannabinoid receptors and enzymes. This system is involved in the proper maintenance of a wide range of bodily functions.
CBD indirectly interacts with these receptors, whereas CBG directly acts upon them. It is through this differentiation of interaction that we believe CBG can have different effects from CBD. A quick search on Google will highlight what these can be.
Our CBG Hemp Oil is rich in CBG, but also in CBD. It has a 1:1 ratio of CBG to CBD in order to have the most significant impact on the endocannabinoid system. Furthermore, it contains both CBD and CBG in its acidic forms and a wide range of additional cannabinoids and terpenes.
Due to the huge variation of compounds within this product, it tends to have more pronounced effects than standard CBD oils of the same strength. Customers tend to be surprised at just how effective it is with the seemingly low 3 per cent concentration.
We believe this is due to the ‘entourage effect’ which is a phenomenon where compounds interact synergistically which results in stronger effects for the user. This has been demonstrated in several studies.
If you are interested in learning more about our CBG Hemp Oil and other effective products, head over to our website today – www.brownscbd.com
Study shows legalisation has no adverse effects on neonatal health outcomes
The team of researchers assessed the influence of statewide cannabis liberalisation policies on newborn health
A new study on the effects of legalising cannabis for adult or therapeutic use shows no adverse effects on neonatal health outcomes at the population level.
The neonatal study was published in the Journal of Health Economics and shows that legalising cannabis for adult use is not associated with adverse effects on neonatal health outcomes.
The team of researchers from Columbia University, University of North Carolina and Indiana University assessed the influence of statewide cannabis liberalisation policies on newborn health over 12 years starting in 2007.
They discovered that the proportion of maternal hospitalisations from cannabis use disorder increased by 23 percent in the first three years of legalisation with larger percentages in states where commercial sales were allowed. This was accompanied by a decrease of 7 percent in tobacco use disorder hospitalisations.
Legalised cannabis was not associated with any significant changes in newborn health according to the study. Medical cannabis laws had no statistically significant effect on maternal substance use disorder hospitalisations or on newborn health.
The authors wrote: “There is no statistically significant effect of medical cannabis laws on the proportion of newborn hospitalisations with prenatal exposure to noxious substances, neonatal drug withdrawal syndrome, fetal alcohol syndrome, slow growth, respiratory conditions, feeding problems, congenital abnormalities, low gestational age, low birth weight, or very low birth weight. Likewise, recreational cannabis laws appear to have no effect on these outcomes.”
They concluded, “In absolute numbers, our findings implied modest or no adverse effects of cannabis liberalisation policies on the array of perinatal outcomes considered.” However, they cautioned, “Our null findings do not refute nor support an argument that prenatal exposure to cannabis has negative effects on newborn health outcomes, but rather that state cannabis liberalisation policies are not associated with net changes at the population-level that are statistically detectable or economically meaningful.”
Other studies assessing the potential effects of cannabis use during perinatal health are inconsistent. Some studies link cannabis use to lower birth weights but failed to adjust methods to account for contributing factors such as tobacco smoking.
A study conducted during the pandemic revealed that cannabis use among pregnant women has increased during lockdown.
Researchers from Kaiser Permanente analysed figures of pregnant women consuming cannabis in Northern California during the pandemic to the numbers from the previous year.
The study involved analysing urine toxicology tests of more than 95,000 women having their first prenatal visit in Northern California Kaiser Permanente. They collected the tests between January 2019 and December 2020 before comparing them to tests from 15 months prior to the start of the pandemic. The results showed a 25 percent increase in the rate of cannabis consumption. Prior to the pandemic, the rates of pregnant women using cannabis were at 6.75 percent. This rose to 8.14 percent during the lockdown.
Clint Eastwood wins $6m in damages from CBD company in lawsuit
The actor’s image was used to promote a CBD company that he had no affiliation or promotional ties with.
Clint Eastwood is just one of many celebrities who have had their images used to promote CBD companies in recent years despite not having an affiliation with the brand.
The actor Clint Eastwood was awarded $6.1 million on Friday in a lawsuit against a Lithuanian CBD company that was accused of using his image and likeness to endorse their products. Eastwood filed two lawsuits against three CBD manufacturers and marketers last year after they claimed he endorsed CBD products in an online article. He also filed against 10 online retailers who were accused of manipulating search results through their meta tags.
Clint Eastwood lawsuit
Eastwood’s lawyers filed an amended complaint in February 2021 against Mediatonas UAB, the company that owns the website where the stories appear. While the court was in agreement that he and Garrapata, the company that owns his image, were entitled to damages, they did not allow for defamation claims noting that the language used was not libellous. The company failed to respond to the summons issued last March.
Eastwood has no connection of any kind whatsoever to any CBD products, the plaintiffs said in court.
The original complaint, filed in July 2020, named as defendants the companies whose products were being advertised in the article. In February, Eastwood’s lawyers filed an amended complaint against Mediatonas UAB, the company that owns the websites where the false stories appear. They will also have to pick up the costs for Eastwood’s legal team.
The original story shared a false online interview that featured the actor claiming he had left filming to start a CBD line.
Clint Eastwood is not the only celebrity to have their image used to promote CBD brands they are not affiliated with. Tom Hanks, Russell Brand and Mary Berry have all found themselves advertising products online.
Celebrity endorsements can be used to make customers feel more confident about buying a product or a particular brand. Some celebrities do actually endorse CBD products such as Claudia Winkleman for Cannaray. She signed a deal with the company after revealing that she used CBD to combat stress during lock down.
Introducing our new B2B title
- Menopause and medical cannabis – how we’re tackling the stigma
- ADHD: “I wasn’t naughty, the world just looked different to me”
- British footballer sentenced to 25 years in Dubai jail over CBD
- CBD brand teams up with Welsh artist to highlight emotions of lockdown
- Breast milk of THC-positive mothers not harmful to short-term health of infants – study
- Combining CBD and CBG for the ultimate entourage effect
News11 months ago
Community extends support to cannabis icon Rick Simpson
News1 year ago
NHS lines up cannabis medicine manufacturing
Case Studies2 years ago
CBD oil and fibromyalgia – a case study
News1 year ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Insight1 year ago
I’ve gone from a wheelchair to walking thanks to cannabis
News9 months ago
UK grants second licence to grow high-THC medical cannabis
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News11 months ago
Living with chronic fatigue – my CBD story